Test Detail

Molecular test for hereditary polyneuropathy of the Alaskan Malamute (AMPN), a peripheral neuropathy of juvenile onset that produces progressive weakness, muscle atrophy and motor dysfunction. It affects the peripheral nervous system and compromises exercise and quality of life; in some cases it is associated with dyspnea due to laryngeal involvement. The test reports clear/carrier/affected status for the corresponding variant.

Applicable breed: Alaskan Malamute. No published population carrier frequencies are available; OMIA:002120 documents the variant in the breed.

- Genotype breeding dogs before mating\n- While the mode of inheritance is being confirmed, treat the molecular status with caution: avoid mating two carriers\n- An affected animal should not be bred; a carrier can be mated to a clear dog without producing affected offspring\n- After a confirmed clinical case, do not repeat the parental mating and communicate the status to the buyer

AMPN is a differential diagnosis with other northern polyneuropathies (e.g. Leonberger LPN, Greater Swiss Mountain Dog polyneuropathy) and with hereditary myopathies (e.g. Labrador myopathy, storage myopathy). Electromyography and nerve conduction studies guide the diagnosis. Rule out acquired causes (toxic, endocrine, paraneoplastic) before attributing the picture to AMPN.

1. Bruun CS et al. 2013. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One 8:e54547. PMID: 23393557
2. Jäderlund KH et al. 2017. Re-emergence of hereditary polyneuropathy in Scandinavian Alaskan malamute dogs - old enemy or new entity? A case series. Acta Vet Scand 59:26. PMID: 28464941
3. OMIA:002120-9615 - Polyneuropathy, NDRG1-related. https://omia.org/OMIA002120/9615/